Literature DB >> 24500412

Neuropathic pain: mechanisms and their clinical implications.

Steven P Cohen1, Jianren Mao.   

Abstract

Neuropathic pain can develop after nerve injury, when deleterious changes occur in injured neurons and along nociceptive and descending modulatory pathways in the central nervous system. The myriad neurotransmitters and other substances involved in the development and maintenance of neuropathic pain also play a part in other neurobiological disorders. This might partly explain the high comorbidity rates for chronic pain, sleep disorders, and psychological conditions such as depression, and why drugs that are effective for one condition may benefit others. Neuropathic pain can be distinguished from non-neuropathic pain by two factors. Firstly, in neuropathic pain there is no transduction (conversion of a nociceptive stimulus into an electrical impulse). Secondly, the prognosis is worse: injury to major nerves is more likely than injury to non-nervous tissue to result in chronic pain. In addition, neuropathic pain tends to be more refractory than non-neuropathic pain to conventional analgesics, such as non-steroidal anti-inflammatory drugs and opioids. However, because of the considerable overlap between neuropathic and nociceptive pain in terms of mechanisms and treatment modalities, it might be more constructive to view these entities as different points on the same continuum. This review focuses on the mechanisms of neuropathic pain, with special emphasis on clinical implications.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24500412     DOI: 10.1136/bmj.f7656

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  186 in total

1.  Role of Kv4.3 in Vibration-Induced Muscle Pain in the Rat.

Authors:  Lindsay B Conner; Pedro Alvarez; Oliver Bogen; Jon D Levine
Journal:  J Pain       Date:  2015-12-22       Impact factor: 5.820

2.  Repurposing a leukocyte elastase inhibitor for neuropathic pain.

Authors:  Andy D Weyer; Cheryl L Stucky
Journal:  Nat Med       Date:  2015-05       Impact factor: 53.440

Review 3.  Drug therapy for chronic idiopathic axonal polyneuropathy.

Authors:  Janna Warendorf; Alexander Fje Vrancken; Ivo N van Schaik; Richard Ac Hughes; Nicolette C Notermans
Journal:  Cochrane Database Syst Rev       Date:  2017-06-20

Review 4.  CRMPs: critical molecules for neurite morphogenesis and neuropsychiatric diseases.

Authors:  T T Quach; J Honnorat; P E Kolattukudy; R Khanna; A M Duchemin
Journal:  Mol Psychiatry       Date:  2015-06-16       Impact factor: 15.992

5.  LRP1 deficiency in microglia blocks neuro-inflammation in the spinal dorsal horn and neuropathic pain processing.

Authors:  Coralie Brifault; HyoJun Kwon; Wendy M Campana; Steven L Gonias
Journal:  Glia       Date:  2019-02-11       Impact factor: 7.452

6.  Hyperbaric oxygen treatment attenuates neuropathic pain by elevating autophagy flux via inhibiting mTOR pathway.

Authors:  Yong-Da Liu; Zhi-Bin Wang; Guang Han; Ping Zhao
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

Review 7.  A comprehensive review of pulsed radiofrequency in the treatment of pain associated with different spinal conditions.

Authors:  Giancarlo Facchini; Paolo Spinnato; Giuseppe Guglielmi; Ugo Albisinni; Alberto Bazzocchi
Journal:  Br J Radiol       Date:  2017-02-10       Impact factor: 3.039

Review 8.  EphBs and ephrin-Bs: Trans-synaptic organizers of synapse development and function.

Authors:  Nathan T Henderson; Matthew B Dalva
Journal:  Mol Cell Neurosci       Date:  2018-07-19       Impact factor: 4.314

9.  Neuromodulation Management of Chronic Neuropathic Pain in The Central Nervous system.

Authors:  Kai Yu; Xiaodan Niu; Bin He
Journal:  Adv Funct Mater       Date:  2020-06-10       Impact factor: 18.808

10.  Contribution of T-Type Calcium Channels to Spinal Cord Injury-Induced Hyperexcitability of Nociceptors.

Authors:  Justas Lauzadis; Huilin Liu; Yong Lu; Mario J Rebecchi; Martin Kaczocha; Michelino Puopolo
Journal:  J Neurosci       Date:  2020-08-24       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.